Accessibility Menu
Xortx Therapeutics logo

Xortx Therapeutics(TSXV) XRTX

Market CapCA$5.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-99%
5 Year-98%
1 Year-45%
1 Month+7%
CA$3.19
+4.59%
+0.14Today
Xortx Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 3.052026-08-27
Xortx Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.02%CAD 2.852026-08-20
1 month+7.39%CAD 2.842026-07-27
3 month-3.48%CAD 3.162026-05-29
Year to date-20.78%CAD 3.852025-12-30
1 year-45.05%CAD 5.552025-08-27
3 year-92.12%CAD 38.702023-08-28
5 year-98.44%CAD 195.472021-08-27
Since inception-98.85%CAD 264.152018-01-11

Xortx Therapeutics Financials at a Glance

Market Cap

CA$5.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.68M

EPS (TTM)

-CA$3.79

P/E Ratio

-0.84

Dividend

CA$0.00

Beta (Volatility)

0.04 (Low)

Price

CA$3.19

Volume

880

Open

CA$3.20

Previous Close

CA$3.19

Daily Range

CA$3.19 - CA$3.20

52-Week Range

CA$2.43 - CA$9.85

Estimated Earnings Date

Nov 12, 2026

XRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xortx Therapeutics

XORTX Therapeutics Inc. is a biopharmaceutical company based in Vancouver, Canada, focused on developing innovative treatments for progressive kidney disorders, diabetes, and related conditions. The company is advancing several promising therapies through its clinical pipeline, aiming to address significant unmet medical needs.

Products and Services
  • XRx-008 targets autosomal dominant polycystic kidney disease
  • XRx-101 aims to reduce uric acid levels in COVID-19 patients
  • XRx-221 includes xanthine oxidase inhibitors for diabetic nephropathy
Growth Outlook
  • Collaboration with Icahn School of Medicine enhances research capabilities
  • Focus on progressive kidney disorders aligns with increasing global health concerns
  • Potential market expansion as therapies progress through clinical trials
Financial Highlights
  • Recent quarterly net income of -$1.65 million reflects ongoing R&D investments
  • Cash and cash equivalents of $992,428 provide operational runway
  • Current ratio of 3.59 indicates strong liquidity position
XORTX Therapeutics Inc. is positioned in a critical sector of healthcare, focusing on conditions that affect millions globally. The company's innovative pipeline, including late-stage clinical programs, demonstrates its commitment to addressing significant health challenges. The collaboration with a prestigious medical institution further strengthens its research capabilities, potentially leading to breakthroughs in treatment options. Financially, while the company is currently operating at a loss, the substantial cash reserves and strong liquidity ratios suggest a solid foundation for future growth. The focus on progressive kidney disorders and related conditions aligns with increasing global health concerns, indicating a promising market opportunity as therapies advance through clinical trials.
AI Generated • Aug 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

17

CEO

Allen Warren Davidoff, PhD; Mika Grasso

Website

www.xortx.com

Headquarters

Calgary, AB T2L 2M1, CA

XRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-126.96%

Return on Capital

-156.43%

Return on Assets

-59.67%

Earnings Yield

-1.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$5.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.82M

Volume

880

Avg. Volume

347.813

Financials (TTM)

Gross Profit

-$101.89K

Operating Income

-$3.86M

EBITDA

-$3.69M

Operating Cash Flow

-$5.00M

Capital Expenditure

$3.63M

Free Cash Flow

-$1.84M

Cash & ST Invst.

$992.43K

Total Debt

$0.00

Xortx Therapeutics Performance Analysis

Xortx Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Xortx Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Xortx Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -32.05324.5%
20232023-12-31USD -7.35-77.1%
20242024-12-31USD -7.887.3%
20252025-12-31USD -3.92-50.3%
Xortx Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3031.6%
Q42025-12-3127.1%
Q12026-03-3175.9%
Q22026-06-30-78.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$17.85K

+53.4%

Gross Margin

0.00%

N/A

Market Cap

CA$5.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.90M

N/A

Employees

2

N/A

Net Income

-$1.65M

-129.5%

EBITDA

-$1.63M

-88.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$992.43K

-6.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$87.95K

+709.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-59.67%

N/A

Return on Invested Capital

-70.27%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

-$3.17M

-299.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APS.TOAptose Biosciences Inc.
CA$2.40+0.00%
LFST.VLifeist Wellness Inc.
CA$0.06-8.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About XRTX

What is the current price of Xortx Therapeutics?

Xortx Therapeutics is trading at CA$3.19 per share.

What is the 52-week range for Xortx Therapeutics?

Over the past 52 weeks, Xortx Therapeutics has traded between CA$2.43 and CA$9.85.

How much debt does Xortx Therapeutics have?

As of the most recent reporting period, Xortx Therapeutics reported total debt of $0.00.

How much cash does Xortx Therapeutics have on hand?

Xortx Therapeutics reported $1.41M in cash and cash equivalents in its most recent financial results.

What is Xortx Therapeutics’s dividend yield?

Xortx Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services